Hypha’s Q2 2022 newsletter features synthesis of GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and information on our late-stage oxidation kits.
Hypha’s new service for accessing API degradation products and impurities is featured in our Q1 2022 newsletter. Also highlighted is the CYP active site engineering our Recombinant Technologies Team have undertaken to further develop PolyCYPs enzymes.
In our Q4 2021 technical newsletter we describe how Hypha used PolyCYPs to help the Open Source Antibiotics team identify a drug metabolite.
We’re pleased to welcome Dr Samuel Coe to the team at Hypha as Business Development Manager. Samuel is a medicinal chemist by training having previously worked in the pharma space for Vertex, Charnwood Molecular and Evotec.
Frank will be giving a talk at the EFMC-ISMC 2021 meeting on “Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using PolyCYPs Enzymes”
We’re proud of our team for the recent successful delivery of a client project using Hypha’s One-Stop Metabolite Shop approach. Metabolites of two drug substances were provided, using microbial biotransformation for one drug compound and late-stage chemical synthesis for the other.
We always really appreciate receiving feedback from a client. This time we celebrate project success for Alkermes for whom we used our PolarExplorer platform to deliver novel hydroxylated derivatives of some of their lead compounds. PolarExplorer uses Hypha’s PolyCYPs enzymes to create multiple hydroxylated derivatives of drugs in parallel.
Our newsletter for Q1 2021 features a commentary on the perceived increase in requests to access N-glucuronides, as well as highlighting Hypha’s solutions for synthesising and characterizing these and other types of glucuronide metabolites, as part of the tools in our One-Stop Metabolite Shop approach.
Project Manager and Head of Chemistry Richard Phipps, together with Hypha scientists Renia Gemmell, Chloe Herring and Chris Drake have received great feedback for the successful completion of a challenging metabolite project for a US pharma client. The project involved multiple disciplines of microbial biotransformation, purification and structure elucidation.
Stay up to date with the latest news from Hypha Discovery
Sign up for our Newsletter to receive interesting updates and scientific case studies about Hypha’s metabolite generation capabilities and lead optimization solutions
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.